Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

efatutazone × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Head & Neck 2 Gastrointestinal 2 Endocrine 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma 1

Interventions

Rituximab 1264 Cyclophosphamide 1171 Vincristine 598 Doxorubicin 534 Etoposide 475 Prednisone 460 Cytarabine 430 fludarabine 416 Methotrexate 385 Dexamethasone 363 fludarabine phosphate 353 Lenalidomide 321 Filgrastim 311 Bendamustine Hydrochloride 248 Radiotherapy 245 venetoclax 234 ibrutinib 231 obinutuzumab 211 Melphalan 208 Peripheral Blood Stem Cell Transplantation 204 Granulocyte Colony-Stimulating Factor 183 Gemcitabine 182 Bortezomib 177 Busulfan 166 Whole-Body Irradiation 165 Mycophenolic Acid 154 Tacrolimus 136 Magnetic Resonance Spectroscopy 132 Calcium Dobesilate 130 Specimen Handling 129

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01504490 2017-02-14

Phase I Study of CS-7017 and Bexarotene

Georgetown University

Phase 1 Terminated

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡